Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03945773
Title Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint)
Acronym CaboPoint
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ipsen
Age Groups: adult | senior
Covered Countries NLD | GBR | FRA | ESP | DEU | AUT

No variant requirements are available.